Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value -0.01% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTEton Pharmaceuticals, Inc.'s latest supported as-filed period reports revenue of $37.6M, 98.6% above the comparable as-filed period; gross margin moved 461 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value -0.01% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 19.30% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 98.59% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 26.98% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 67.61% · CORE
Level · gp.fundamentals.operating_margin
Raw value 34.04% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 98.6%; Operating margin moved 4183 bp higher; Operating income changed across a sign change.
3 evidence-backed componentsOperating margin changed +4183 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ETON · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001437749-26-029308SEC ↗4Aug 28, 2026Period Aug 28, 20260001437749-26-029196SEC ↗4Aug 24, 2026Period Aug 24, 20260001437749-26-028846SEC ↗4Aug 20, 2026Period Aug 19, 20260001437749-26-028651SEC ↗10-QAug 13, 2026Period Jun 30, 20260001437749-26-027684SEC ↗8-KAug 13, 2026Period Aug 13, 20260001437749-26-027672SEC ↗8-KAug 5, 2026Period Jul 31, 20260001437749-26-025781SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 28, 2026Filed Aug 31, 2026 | MAIER PAUL VDirector | Option ExerciseDirect · amended | 50,000 | $4 | $189,000 | Form 4 ↗ |
| Aug 28, 2026Filed Aug 31, 2026 | MAIER PAUL VDirector | Open Market SaleDirect · amended | 36,387 | $59 | $2.1M | Form 4 ↗ |
| Aug 28, 2026Filed Aug 31, 2026 | MAIER PAUL VDirector | Open Market SaleDirect · amended | 13,485 | $60 | $811,932 | Form 4 ↗ |
| Aug 28, 2026Filed Aug 31, 2026 | MAIER PAUL VDirector | Open Market SaleDirect · amended | 128 | $62 | $7,907 | Form 4 ↗ |
| Aug 28, 2026Filed Aug 31, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 2.64% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 3.91% · OPTIONAL
Revenue changed +98.6% from the comparable as-filed period.
Gross margin changed +461 basis points from the comparable as-filed period.
Inventory changed -57.4% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Research & development changed -73.2% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Gross profit changed +113.1% from the comparable as-filed period.
Inventory / revenue changed -9871 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001437749-26-025725| MAIER PAUL VDirector |
| Option ExerciseDirect · amended |
| 12,500 |
| $7 |
| $91,375 |
| Form 4 ↗ |
| Aug 28, 2026Filed Aug 31, 2026 | MAIER PAUL VDirector | Option ExerciseDirect · amended | 50,000 | $0 | $0 | Form 4 ↗ |
| Aug 28, 2026Filed Aug 31, 2026 | MAIER PAUL VDirector | Option ExerciseDirect · amended | 12,500 | $0 | $0 | Form 4 ↗ |
| Aug 24, 2026Filed Aug 24, 2026 | Krempa DavidChief Business Officer | Option ExerciseDirect | 25,000 | $7 | $182,750 | Form 4 ↗ |
| Aug 24, 2026Filed Aug 24, 2026 | Krempa DavidChief Business Officer | Open Market SaleDirect | 25,000 | $65 | $1.6M | Form 4 ↗ |
| Aug 24, 2026Filed Aug 24, 2026 | Krempa DavidChief Business Officer | Option ExerciseDirect | 25,000 | $0 | $0 | Form 4 ↗ |